CL2017000827A1 - Inhibidores de aldosterona sintasa - Google Patents

Inhibidores de aldosterona sintasa

Info

Publication number
CL2017000827A1
CL2017000827A1 CL2017000827A CL2017000827A CL2017000827A1 CL 2017000827 A1 CL2017000827 A1 CL 2017000827A1 CL 2017000827 A CL2017000827 A CL 2017000827A CL 2017000827 A CL2017000827 A CL 2017000827A CL 2017000827 A1 CL2017000827 A1 CL 2017000827A1
Authority
CL
Chile
Prior art keywords
compounds
synthase inhibitors
aldosterone synthase
processes
refers
Prior art date
Application number
CL2017000827A
Other languages
English (en)
Inventor
Simon Surprenant
Keith R Hornberger
Kenneth Michael Meyers
Peter Allen Nemoto
Hui Yu
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54352516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000827(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2017000827A1 publication Critical patent/CL2017000827A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A LOS COMPUESTOS DE LA FORMULA I, Y SUS SALES FARMACÉUTICAMENTE ACEPTABLES, EN DONDE R 1, R2 Y R3 SON COMO SE DEFINEN EN LA PRESENTE. LA INVENCIÓN TAMBIÉN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN ESTOS COMPUESTOS, USOS DE ESTOS COMPUESTOS EN EL TRATAMIENTO DE DIVERSAS  ENFERMEDADES Y TRASTORNOS, PROCESOS PARA PREPARAR ESTOS COMPUESTOS E INTERMEDIARIOS ÚTILES EN ESTOS PROCESOS.</p>
CL2017000827A 2014-10-15 2017-04-05 Inhibidores de aldosterona sintasa CL2017000827A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462064234P 2014-10-15 2014-10-15

Publications (1)

Publication Number Publication Date
CL2017000827A1 true CL2017000827A1 (es) 2017-11-03

Family

ID=54352516

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000827A CL2017000827A1 (es) 2014-10-15 2017-04-05 Inhibidores de aldosterona sintasa

Country Status (33)

Country Link
US (1) US9745289B2 (es)
EP (1) EP3207039B1 (es)
JP (1) JP6279812B2 (es)
KR (1) KR102441634B1 (es)
CN (1) CN107108587B (es)
AP (1) AP2017009829A0 (es)
AR (1) AR102266A1 (es)
AU (1) AU2015333611B2 (es)
CA (1) CA2964754C (es)
CL (1) CL2017000827A1 (es)
CO (1) CO2017003305A2 (es)
CY (1) CY1121650T1 (es)
DK (1) DK3207039T3 (es)
EA (1) EA031766B1 (es)
ES (1) ES2724555T3 (es)
HR (1) HRP20190896T1 (es)
HU (1) HUE043783T2 (es)
IL (1) IL251200B (es)
LT (1) LT3207039T (es)
ME (1) ME03381B (es)
MX (1) MX369025B (es)
NZ (1) NZ729688A (es)
PE (1) PE20170696A1 (es)
PH (1) PH12017500595B1 (es)
PL (1) PL3207039T3 (es)
PT (1) PT3207039T (es)
RS (1) RS58651B1 (es)
SG (1) SG11201701850UA (es)
SI (1) SI3207039T1 (es)
TR (1) TR201907755T4 (es)
TW (1) TWI731842B (es)
UA (1) UA118717C2 (es)
WO (1) WO2016061161A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6707084B2 (ja) * 2014-12-02 2020-06-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルドステロンシンターゼ阻害薬
WO2020223267A1 (en) 2019-05-01 2020-11-05 Boehringer Ingelheim International Gmbh (r)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate
CA3192236A1 (en) 2020-09-10 2022-03-17 Tony Lahoutte Antibody fragment against fap
WO2023114170A1 (en) 2021-12-14 2023-06-22 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors for treating chronic kidney disease
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR073629A1 (es) * 2008-10-07 2010-11-17 Schering Corp Analogos de benzodioxano moduladores de receptores adrenergicos alfa 2c, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades respiratorias, alergicas, cardiacas, parkinson y/o alzheimer, entre otras
SI2429995T1 (sl) 2009-05-15 2014-05-30 Novartis Ag Arilpiridini kot inhibitorji aldosteron sintaze
SI2785695T1 (sl) * 2011-11-30 2020-10-30 F. Hoffmann-La Roche Ag Novi biciklični derivati dihidroizokinolin-1-ona
WO2014055595A1 (en) * 2012-10-05 2014-04-10 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitiors related applications
CA2898482A1 (en) * 2013-02-22 2014-08-28 Linda L. Brockunier Antidiabetic bicyclic compounds
US9181272B2 (en) * 2013-04-30 2015-11-10 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
WO2016014736A1 (en) * 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors

Also Published As

Publication number Publication date
AP2017009829A0 (en) 2017-03-31
JP2017531016A (ja) 2017-10-19
CN107108587A (zh) 2017-08-29
EA201790830A1 (ru) 2017-09-29
EP3207039B1 (en) 2019-03-06
KR20170066651A (ko) 2017-06-14
ME03381B (me) 2020-01-20
EA031766B1 (ru) 2019-02-28
DK3207039T3 (en) 2019-04-23
PH12017500595A1 (en) 2017-08-30
AU2015333611B2 (en) 2020-02-06
UA118717C2 (uk) 2019-02-25
IL251200A0 (en) 2017-05-29
JP6279812B2 (ja) 2018-02-14
HRP20190896T1 (hr) 2019-07-12
KR102441634B1 (ko) 2022-09-13
MX2017004852A (es) 2017-06-22
TWI731842B (zh) 2021-07-01
IL251200B (en) 2019-05-30
PE20170696A1 (es) 2017-06-07
CA2964754A1 (en) 2016-04-21
SI3207039T1 (sl) 2019-05-31
CA2964754C (en) 2023-01-24
ES2724555T3 (es) 2019-09-12
AU2015333611A1 (en) 2017-03-23
PH12017500595B1 (en) 2017-08-30
NZ729688A (en) 2020-05-29
PT3207039T (pt) 2019-06-04
AR102266A1 (es) 2017-02-15
LT3207039T (lt) 2019-05-10
TR201907755T4 (tr) 2019-06-21
US20160108026A1 (en) 2016-04-21
RS58651B1 (sr) 2019-05-31
BR112017005859A2 (pt) 2017-12-26
HUE043783T2 (hu) 2019-09-30
CN107108587B (zh) 2020-05-22
MX369025B (es) 2019-10-25
WO2016061161A1 (en) 2016-04-21
TW201629048A (zh) 2016-08-16
PL3207039T3 (pl) 2019-08-30
CO2017003305A2 (es) 2017-07-19
EP3207039A1 (en) 2017-08-23
CY1121650T1 (el) 2020-07-31
US9745289B2 (en) 2017-08-29
SG11201701850UA (en) 2017-04-27

Similar Documents

Publication Publication Date Title
ECSP21008112A (es) Compuestos de pirrolotriazina como inhibidores de tam
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
CL2017000992A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasa
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
CL2017000712A1 (es) Pirimidinonas como inhibidores del factor xia
CL2017001050A1 (es) Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
DOP2016000173A (es) Heteroarilos y usos de estos
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
ECSP17021897A (es) Compuestos y composiciones como inhibidores de quinasa raf
DOP2016000194A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
CU20160052A7 (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
GT201700099A (es) 2- amino-6-(difluorometil)-5,5-difluoro-6-fenil-3, 4, 5, 6-tetrahidropiridinas como inhibidores de bace1
CO2017005588A2 (es) 2-amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CL2019000476A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
ECSP16074478A (es) Compuestos novedosos
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
GT201700058A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
CL2017000040A1 (es) Inhibidores de aldosterona sintasa.